Composite Atherogenic Indices and Bama Longevity Lipids (2026 Study)
Educational review context: Longevity paper explainers on RevGenetics are framed for science literacy, not clinical care. Dr. Hector Valenzuela, Fletcher Jones Chair in Molecular Biology and Biology Department Chair at Whittier College, with prior UCLA Pathology training in T-cell aging and senescence biology, is the founder-scientist whose peer-reviewed work anchors that education program. For his publication list and related research pages, see Dr. Hector Valenzuela scientific publications. This byline is academic. It is not a product pitch.
Longevity regions get a lot of attention for diet, lifestyle, and genetics. Lipid bloodwork is often part of that story. A common mistake is to treat one conventional number, such as LDL-C alone, as the whole picture of atherogenic risk.
A 2026 research article in Scientific Reports asks a longevity-relevant question: do composite atherogenic indices show a less atherogenic lipid pattern in people from China's Bama longevity area compared with controls from a non-longevity region? The paper reports that several composite indices were lower in Bama participants. The longer answer requires keeping the study design clear. This was observational and cross-sectional only. It was not a treatment trial, and it does not prove that any product caused Bama longevity or treats cardiovascular disease.
Source: Zhang J, Chen Z, Lu B, et al. Composite atherogenic indices reveal a superior lipid profile in a Chinese longevity population: a cross-sectional cohort study. Sci Rep (2026). Article in press. Received 31 Oct 2025; accepted 16 Jun 2026. doi:10.1038/s41598-026-58722-5
Quick answer
In a cross-sectional cohort of 2,767 plasma donors (Bama longevity area, Guangxi, n=1,007; Shimen County, Hunan controls, n=1,760), Bama participants had lower AIP, AI, LCI, RC, and CRI-I (all P<0.001; Cohen's d from -0.23 to -1.04). CRI-II was not significantly different (P=0.141). Bama also had higher HDL-C and, notably, higher LDL-C than controls. That contrast is the educational hook: a conventional LDL number can look different from the composite atherogenic profile. This was observational only, not an intervention trial.
Cite this summary (journalists / creators): "Bama longevity-area donors showed lower composite atherogenic indices (AIP, AI, LCI, RC, and CRI-I) than Shimen controls, even while mean LDL-C was higher. Cross-sectional only." Source: Zhang et al., Sci Rep 2026. doi:10.1038/s41598-026-58722-5. Not a treatment study.
What are composite atherogenic indices?
Definition: composite atherogenic indices
Composite atherogenic indices combine more than one lipid fraction into a single score. The idea is that atherogenic risk often reflects interactions among triglycerides (TG), HDL-C, LDL-C, and total cholesterol (TC), not only one isolated value. In this paper, the panel included AIP, AI, LCI, RC, CRI-I, and CRI-II.
Definition: AIP (atherogenic index of plasma)
AIP is calculated as log(TG/HDL-C). It is used in research as a marker of plasma atherogenicity that emphasizes the balance between triglycerides and HDL-C. In this study, AIP correlated very strongly with TG (r=0.933).
Definition: RC (remnant cholesterol)
RC is calculated as TC - HDL-C - LDL-C. It estimates cholesterol carried in triglyceride-rich remnant lipoproteins. In this study, RC correlated strongly with TG (r=0.700). The authors highlight RC as part of an integrated atherogenic picture beyond LDL-C alone.
Other indices used in the paper:
- AI (atherogenic index) = non-HDL-C / HDL-C
- LCI (lipoprotein combine index) = (TC × TG × LDL-C) / HDL-C
- CRI-I (Castelli's risk index I) = TC / HDL-C
- CRI-II (Castelli's risk index II) = LDL-C / HDL-C
AI and CRI-I both showed strong negative correlations with HDL-C (r=-0.728 for both). LCI correlated strongly with TG (r=0.882).
Why Bama lipids matter for longevity education
Bama County in Guangxi is often discussed as a Chinese longevity hotspot. Prior work on this plasma-donor cohort reported more favorable conventional lipids in Bama versus Shimen (higher HDL-C, lower TG). The 2026 paper extends that work by applying composite atherogenic indices to the same longevity-versus-control frame.
For longevity readers, the educational value is mechanistic literacy about lipid ratios and remnant-related measures. It is not a recipe for "how to become Bama." Genetics, local environment, diet patterns, and selection into a plasmapheresis donor pool all sit outside any single blog takeaway.
Who was studied (cross-sectional cohort)
Researchers enrolled 2,767 participants from two plasmapheresis centers between June and November 2018:
- Bama longevity area (Guangxi): n=1,007
- Controls, Shimen County (Hunan): n=1,760
Inclusion (high level): age 18-60 years, self-reported good health, in a plasmapheresis context, with additional donor-related exclusions described in the paper (for example relatedness rules and selected medical exclusions).
Design note: This is a cross-sectional comparison at one window in time. It does not follow people into future heart events, and it does not assign a treatment.
Baseline differences included:
- Bama younger: 45.16±8.29 vs 49.50±6.09 years
- Bama higher HDL-C: 1.11±0.32 vs 0.97±0.25 mmol/L
- Bama higher LDL-C: 2.53±0.70 vs 2.28±0.56 mmol/L (P<0.001)
That last point is intentional teaching material. If you only glance at mean LDL-C, Bama does not look "lower LDL." The composite indices tell a different story.
What the composite indices showed
Across most composite measures, the Bama cohort showed a significantly less atherogenic profile than controls:
| Index | Direction in Bama vs controls | Significance / effect |
|---|---|---|
| AIP | Lower | P<0.001; within Cohen's d -0.23 to -1.04 |
| AI | Lower | P<0.001; within Cohen's d -0.23 to -1.04 |
| LCI | Lower | P<0.001; within Cohen's d -0.23 to -1.04 |
| RC | Lower | P<0.001; within Cohen's d -0.23 to -1.04 |
| CRI-I | Lower | P<0.001; within Cohen's d -0.23 to -1.04 |
| CRI-II | Not significantly different | P=0.141 |
The paper notes that differences for AIP and RC were among the most pronounced in the panel. A sensitivity analysis adjusting for age and sex still supported lower AIP, AI, LCI, RC, and CRI-I in Bama, while CRI-II remained nonsignificant.
Why CRI-II may not have moved: CRI-II is LDL-C/HDL-C. Bama had both higher HDL-C and higher LDL-C, which can offset each other in that ratio. Indices that incorporate TG metabolism (such as AIP and RC) or a broader lipoprotein mix (such as AI and LCI) captured the between-group difference more clearly.
Correlations: what the indices track
Across the full cohort (N=2,767), Spearman correlations helped explain what each score "listens to":
- AIP, LCI, and RC were strongly positive with TG (r=0.933, 0.882, and 0.700)
- AI and CRI-I were strongly negative with HDL-C (r=-0.728 for both)
Plain-language takeaway: In this dataset, several "less atherogenic" composite scores in Bama aligned with triglyceride and HDL-related patterns, not with a simple story of lower LDL alone.
The LDL educational hook (read carefully)
This is the shareable teaching point for longevity audiences:
- Bama donors had higher mean LDL-C than Shimen controls.
- The same Bama group still had lower AIP, AI, LCI, RC, and CRI-I.
- Therefore, reading LDL-C in isolation can miss composite atherogenic context that includes TG, HDL-C, remnants, and multi-fraction ratios.
The authors discuss possible biological interpretations (for example lipoprotein quality or particle features) as hypotheses. Those mechanisms were not directly measured here. Treat that discussion as scientific context, not as proven cause of Bama longevity.
How to read this study (observational only)
| Question | What this paper did | What it did not do |
|---|---|---|
| Design | Cross-sectional cohort comparison | Longitudinal event follow-up or RCT |
| Population | Plasmapheresis donors, age 18-60, self-reported good health | Random sample of all ages in Bama or Shimen |
| Main lipid message | Several composite indices lower in Bama; CRI-II NS | Proof that composites "cause" longevity |
| LDL finding | Mean LDL-C higher in Bama | Proof that higher LDL is harmless in general |
| Products / interventions | None tested | No evidence that a supplement or drug created the Bama profile |
Keeping this table in mind is the responsible way to use the paper for education.
What this means for longevity education (not medical advice)
For readers who follow longevity and lipid science, a few durable ideas emerge:
- Composite indices can add context beyond a single lipid number. AIP, RC, AI, LCI, and Castelli ratios integrate fractions that often move together.
- TG and HDL-C patterns mattered in this cohort. Strong correlations with AIP/LCI/RC (TG) and AI/CRI-I (HDL-C) help explain why those scores differed.
- LDL alone can be educationally incomplete. Higher mean LDL-C in Bama alongside lower composite atherogenic indices is a reminder to ask which metric you are interpreting.
- Observational longevity geography is not a treatment protocol. Living in Bama, donating plasma, or sharing a regional mean lipid pattern is not the same as a clinical intervention.
RevGenetics publishes educational content on longevity biology and research literacy. For structured background from the founder-scientist program, see Dr. Hector Valenzuela scientific publications and research. Those pages teach science only. They are not treatments for cardiovascular disease, atherosclerosis, or dyslipidemia. They do not claim to reproduce Bama longevity outcomes, and they are not a substitute for clinical care.
Limitations (read these before sharing the paper)
- Cross-sectional only: Association between region and lipid indices at one time. No causal proof that composite indices explain Bama longevity or future CVD outcomes in these donors.
- Not an intervention trial: No drug, diet protocol, or product was tested as a treatment for atherosclerosis or heart disease.
- Selection / plasmapheresis context: Donors meeting health criteria may not represent the full Bama or Shimen populations.
- Age and other differences: Bama participants were younger on average. The paper reports age/sex-adjusted sensitivity checks for the main index differences, but unmeasured lifestyle factors remain.
- Unmeasured confounders: Diet, physical activity, socioeconomic status, and alcohol were not measured, so those factors cannot be ruled out.
- Fasting status: Fasting was not uniformly required or recorded, which can add variability especially for TG and RC.
- External validity: Bama is a recognized longevity hotspot with unique genetic and environmental context. Findings need external validation elsewhere.
- Apheresis sampling: Plasma collected via apheresis may differ from standard venipuncture absolute concentrations for some lipids.
- Not medical advice: This article is educational. It does not diagnose, treat, cure, or prevent disease. Lipid decisions belong with qualified clinicians.
FAQ
What are composite atherogenic indices?
They are lipid scores that combine more than one cholesterol or triglyceride fraction. This paper used AIP, AI, LCI, RC, CRI-I, and CRI-II to describe atherogenic risk more integratively than a single conventional number.
What did Zhang et al., 2026 find in the Bama cohort?
Bama longevity-area plasma donors had lower AIP, AI, LCI, RC, and CRI-I than Shimen controls (all P<0.001; Cohen's d -0.23 to -1.04). CRI-II was not significantly different (P=0.141).
Did Bama donors have lower LDL-C?
No. Mean LDL-C was higher in Bama (2.53±0.70 vs 2.28±0.56 mmol/L, P<0.001), while HDL-C was also higher. That contrast is why composite indices are educationally useful here.
What is AIP?
AIP = log(TG/HDL-C). In this study it correlated very strongly with triglycerides (r=0.933).
What is remnant cholesterol (RC)?
RC = TC - HDL-C - LDL-C. It estimates cholesterol in triglyceride-rich remnants and correlated strongly with TG (r=0.700) in this cohort.
Was this a treatment study for heart disease?
No. It was a cross-sectional observational comparison. It does not test whether any product treats CVD, atherosclerosis, or longevity.
Why might CRI-II stay nonsignificant?
CRI-II is LDL-C/HDL-C. Higher LDL-C and higher HDL-C in Bama can offset in that ratio, while TG- and remnant-sensitive indices still differ.
What are Castelli risk indices (CRI-I and CRI-II)?
Castelli risk index I (CRI-I) is total cholesterol divided by HDL-C (TC / HDL-C). Castelli risk index II (CRI-II) is LDL-C divided by HDL-C (LDL-C / HDL-C). In this paper, CRI-I was lower in the Bama cohort than in controls, while CRI-II was not significantly different. That split is one reason composite panels matter more than any single ratio.
How does this relate to longevity education?
It shows that longevity-region lipid stories can look different when you use composite atherogenic indices instead of LDL alone. That is a research-literacy lesson, not a product claim.
Bottom line
Zhang and colleagues report that people from the Bama longevity area, sampled as plasma donors, showed a less atherogenic composite lipid profile than Shimen controls across AIP, AI, LCI, RC, and CRI-I, while CRI-II did not differ significantly. The same Bama group had higher mean HDL-C and higher mean LDL-C. For longevity readers, the useful lesson is metric literacy: composite atherogenic indices can reveal a different picture than LDL-C alone.
That lesson stays observational. Cross-sectional differences are not proof of causality, not proof of a consumer protocol, and not evidence that any product treats cardiovascular disease or caused Bama longevity.
Citation: Zhang J, Chen Z, Lu B, et al. Composite atherogenic indices reveal a superior lipid profile in a Chinese longevity population: a cross-sectional cohort study. Sci Rep. 2026 (article in press). doi:10.1038/s41598-026-58722-5
